It is essential that, as the UK’s leading breast cancer charity, we engage with the key stakeholders that will be central to helping stop women dying from the disease. The pharmaceutical industry has a crucial role to play in achieving this vision – and collaborating with the industry is something we know our supporters understand and want us to do.
Organisational pharmaceutical policy
We are open and transparent about our partnerships with the industry. We have agreements in place for each partnership and our work with pharmaceutical companies is underpinned by an organisational pharmaceutical policy. This policy provides clear guidance on how we partner with pharmaceutical and other life sciences companies, including the limits we place on donations as a percentage of our annual income and that we have no preference for working with any one company, and welcome funding from multiple companies where practical and appropriate.
We do not accept specific funding for our policy and campaigns work or use pharmaceutical donations to fund our policy and campaigns work. Where necessary, we will campaign against pharmaceutical companies on issues regarding access to drugs, in the interests of breast cancer patients, regardless of whether Breast Cancer Now is currently receiving funding or has historically received funding from a specific company.
This policy was agreed in 2020 and will next be reviewed in 2022.
2019/20 donations and support
During our 2019/20 financial year, donations from these organisations, amounted to £1.7m. We thank the following companies for their support:
- Daiichi Sankyo
- Eli Lilly
- Exact Sciences
Support included grants towards our face-to-face support services, the Helpline, sponsorship of the UK Breast Cancer Interdisciplinary Symposium and the Service Pledge and the Catalyst Programme.
The Catalyst Programme is an initiative which aims to bring together Europe’s leading breast cancer researchers and the world’s leading pharmaceutical companies to pool resources and stop women dying from breast cancer by 2050. As part of this, Pfizer committed £10 million over three years (2016-2020), which Breast Cancer Now used to award grants to the best proposals from independent researchers.